We envision a future where patients are diagnosed earlier, empowered to monitor themselves, and treatment plans are optimized.
We aim to improve the lives of patients all over the world.
At GLX Analytix, we combine a new, proprietary class of biomarker with AI to bring personalized medicine to your healthcare.
The blood vessels of your body are lined with a natural fuzz.
Winner of Roche Startup Award, Future X Healthcare
Understanding the GLX principle
“Let me explain”
A quick guided intro to how it works and the potential of our approach.
The current lack of biomarkers for chronic illnesses leaves patients and their care-providers in the dark when it comes to diagnosis, treatment and monitoring.
A tool that monitors disease, and predicts attacks, would reduce side effects, improve clinical outcomes and quality of life and be pivotal for testing and approval of new drugs.
We have discovered that an under-estimated and largely forgotten structure on the blood vessel wall, the glycocalyx, is cleaved off by immune cells in specific patterns before they invade the organ to cause harm.
These patterns can be extracted and assembled from a blood sample, like a fingerprint for active disease.
We call this the GLX Signature
In Multiple Sclerosis, a devastating disease attacking the brain, an individual experiences symptoms and receives an MRI. They don’t know if they’ll have relapsing attacks, progress to a wheelchair, or even have no symptoms for the rest of their life. An MRI can only follow brain damage after damage has occurred, and is extremely expensive.
The discovery of the GLX Signature can help. In practice it’s a composite biomarker of inter-related components of the GLX. From these patterns, we build the GLX Signature.
Since our GLX Signature reflects early disease activity, before damage has occurred in the brain, it can be implemented as a monitoring system, both for patient attacks and treatment effect. In some respects, like a blood MRI.
By monitoring this signature, diagnosis improves, and most exciting: attacks can be predicted and treatments monitored in better detail, improving health, and keeping people out of the hospital.
Right treatment, right person, right time
Personalised medicine means not just shifting through the medicine of the day, but also facilitating the discovery, development and market approval of new and better interventions, with less side-effects.
We’re at a pivotal point. We have achieved our first commerical sale, our test, our team and our first partners are in place and we are ready to accelerate on this early traction.
Q1 2021 |
First Commercial Sale
Q1 2021 |
Four key people join the team
Antibody specialist, Mathias Lindh Jørgensen, joins the GLX family.
Biotech Fund Portfolio Manager, Peter Hildebrandt, joins as Chair of the Board.
Lab Technician, Charity Kaphale Graae, joins the GLX family.
Data Scientist, Hjalte Bøgehave, joins the GLX family.
Q1 2020 |
Innovation Fund Denmark
Q4 2019 |
Winner of Roche Future of Healthcare Startup Award
Q4 2019 |
GLX Signature in Stroke
Published in AHA Journal‘Stroke’,over 50% of the 10 GLX markers we measured were significantly increased in patients, with three having a so-called perfect ROC Curve. The GLX Signature gets even more interesting when we feed signals into our deep-learning AI system.
Q4 2019 |
European Innovation & Technology Health – Digital Sandbox
Q1 2019 |
Hysbch Connect Investment Lands
Hybsch Connect Holdings invests into GLX Analytix to take the company off the ground. Indeed an exciting day for everyone involved!
Q2 2018 |
GLX releases before symptoms appear
In preclinical Multiple Sclerosis, GLX markers are increased in the blood days before symptoms debuted. Immune cells may have removed the GLX before the entering the CNS, causing harm. Early diagnosis and prediction of autoimmune attacks may be possibly with GLX Signature monitoring.
The GLX Technology
The glx signature
Our proprietary technology plucks glycocalyx components out from the blood and reassembles the signal through machine learning, producing a GLX fingerprint we call the GLX Signature.
Since the GLX is the first interaction between the blood and the rest of the body, the GLX Signature allows for early diagnosis,before damagehas occured. The GLX Signature doubles as a tool for monitoring flares, treatment response and triples as a companion diagnostic for disease-modifying treatments, accelerating time-to-market through earlier and better patient recruitment, and proof-of-effect, a so-called ‘efficacy test’.
1. Self monitoring
2. GLX Detection
Plucks glycocalyx components out
3. Machine learning
Reassembles the signal through machine learning
We are collaborating with clinicians across over 10 different chronic inflammatory diseases
We are currently collaborating with clinicians across over 10 different chronic inflammatory diseases ranging from autoimmune to psychiatric to neurodegenerative disorders. Contact us below for more information on our progress and how our platform can create value for you.